Dr Clark has 40 years of international experience in governance and executive roles in technology transfer of biomedical and health innovations, both from academic and public research.

Working from senior industry positions in Europe, Asia and North America, Dr Clark has commercialised many products and technologies including drugs, devices, diagnostics, processes and analytical instruments – virtually all having origins in academia.

Dr Clark has most recently been Head of Business Development at the Walter and Eliza Hall Institute (WEHI) and was previously CEO of Faulding Pharmaceuticals (Australia), Pharmacia LKB Biotechnology (now GE and Pfizer, Sweden), Biochrom (UK) and the Cancer Therapeutics CRC (Australia). Amongst many products and technologies successfully brought to market, the drug Venatoclax is a stand-out from Dr Clark’s tenure at WEHI.  Through his consulting company, Dr Clark has assisted more than 100 organisations in Australia with their commercialisation strategies.

Dr Clark has extensive experience in working with more than 20 biomedical boards, recently including Cancer Trials Australia, BioGrid Australia, Nexpep, and Catalyst Therapeutics.

Dr Clark has a PhD from the University of Glasgow and was a post-doctoral fellow at the Karolinska Institute in Stockholm.  A Doctor of the University (Uni SA) and Fellow of the Australia Academy of Technology and Engineering were awarded in recognition of Dr Clark’s significant contributions to technology transfer.